<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">792139</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2021.792139</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Natural Flavonoid Pectolinarigenin Alleviated Hyperuricemic Nephropathy via Suppressing TGF&#x3b2;/SMAD3 and JAK2/STAT3 Signaling Pathways</article-title>
<alt-title alt-title-type="left-running-head">Ren et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Pectolinarigenin Alleviated Hyperuricemic Nephropathy</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ren</surname>
<given-names>Qian</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Bo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1511423/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Fan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Rongshuang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tan</surname>
<given-names>Zhouke</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ma</surname>
<given-names>Liang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/424050/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fu</surname>
<given-names>Ping</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1412744/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Kidney Research Institute, National Clinical Research Center for Geriatrics and Division of Nephrology, West China Hospital of Sichuan University</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Division of Nephrology, ZunYi Medical University Affiliated Hospital</institution>, <addr-line>ZunYi</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/513594/overview">Zhiyong Guo</ext-link>, Second Military Medical University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/581894/overview">Haiyong Chen</ext-link>, The University of Hong Kong, Hong Kong SAR, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1488580/overview">Zhangzhe Peng</ext-link>, Central South University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1147832/overview">Chongxiang Xiong</ext-link>, Third Affiliated Hospital of Guangzhou Medical University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Zhouke Tan, <email>zhouke_tan@163.com</email>; Liang Ma, <email>liang_m@scu.edu.cn</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this&#x20;work</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Renal Pharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>01</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>792139</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>10</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>11</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Ren, Wang, Guo, Huang, Tan, Ma and Fu.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Ren, Wang, Guo, Huang, Tan, Ma and Fu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Natural flavonoid pectolinarigenin (PEC) was reported to alleviate tubulointerstitial fibrosis of unilateral ureteral obstruction (UUO) mice in our previous study. To further investigate nephroprotective effects of PEC in hyperuricemic nephropathy (HN), adenine and potassium oxonate induced HN mice and uric acid-treated mouse kidney epithelial (TCMK-1) cells were employed in the study. As a result, PEC significantly lowered serum uric acid level and restored hyperuricemia-related kidney injury in HN mice. Meanwhile, PEC alleviated inflammation, fibrosis, and reduced adipokine FABP4 content in the kidneys of HN mice and uric acid-treated TCMK-1 cells. Mechanistically, PEC inhibited the TGF-&#x3b2;1 expression as well as the phosphorylation of transcription factor SMAD3 and STAT3 to regulate the corresponding inflammatory and fibrotic gene expression in kidney tissues. In conclusion, our results suggested that PEC could inhibit the activation of SMAD3 and STAT3 signaling to suppress inflammation and fibrosis, and thereby alleviate HN in&#x20;mice.</p>
</abstract>
<kwd-group>
<kwd>hyperuricemic nephropathy</kwd>
<kwd>pectolinarigenin</kwd>
<kwd>renal fibrosis</kwd>
<kwd>inflammation</kwd>
<kwd>fatty acid-binding protein 4</kwd>
</kwd-group>
<contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Key Research and Development Program of Sichuan Province<named-content content-type="fundref-id">10.13039/501100018525</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Hyperuricemia (HUA) is a metabolic disease characterized by elevated uric acid (UA) in blood, the prevalence of which has increased worldwide substantially in recent years (<xref ref-type="bibr" rid="B4">Dehlin et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B3">Dalbeth et&#x20;al., 2021</xref>). Studies showed that HUA was highly associated with diabetes, hypertension, cardiovascular diseases, and chronic kidney diseases (CKD) (<xref ref-type="bibr" rid="B20">Pascart and Liot&#xe9;, 2019</xref>). As serum UA is mainly secreted by the renal proximal tubules, HUA is a frequent finding in person with CKD due to decreased UA clearance (<xref ref-type="bibr" rid="B9">Johnson et&#x20;al., 2013</xref>). In return, recent evidence suggested that HUA independently predicted the development and progression of CKD (<xref ref-type="bibr" rid="B10">Landa, 2018</xref>; <xref ref-type="bibr" rid="B1">Balakumar et&#x20;al., 2020</xref>).</p>
<p>HUA-induced kidney injury, known as hyperuricemic nephropathy (HN), is featured by urate deposition, arteriolosclerosis, glomerular hypertension, and tubulointerstitial fibrosis and would eventually progress into end-stage renal diseases (ESRD) (<xref ref-type="bibr" rid="B17">Liu et&#x20;al., 2015</xref>). The mechanism of HN is complex with many factors such as crystalline effect, oxidative stress, rennin-angiotensin system activation, and tubular epithelial cell transition having been postulated. Though controversial, accumulating data suggested that the UA-lowering treatments could slower the progression of CKD (<xref ref-type="bibr" rid="B18">Liu et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B26">Yanai et&#x20;al., 2021</xref>). Current first-line urate-lowering drugs are mainly xanthine oxidase (XO) inhibitors and uricosuric agents, both of which have limited application in clinics because of their low selectivity or toxic reaction (<xref ref-type="bibr" rid="B1">Balakumar et&#x20;al., 2020</xref>). Hence, it is imperative to develop a new therapeutic agent for&#x20;HN.</p>
<p>Flavonoid pectolinarigenin (PEC), a plant secondary metabolite that has various biological effects, is one of the major compounds in <italic>Cirsium setidens</italic> (<xref ref-type="bibr" rid="B12">Lee et&#x20;al., 2017</xref>). Studies reported that pectolinarigenin conducted antimicrobial, antioxidant, anti-inflammatory, and antidiabetic activities (<xref ref-type="bibr" rid="B2">Cheriet et&#x20;al., 2020</xref>). Meanwhile, PEC was found to suppress lipopolysaccharide-induced inflammation via NF-&#x3ba;B and MAPK pathways (<xref ref-type="bibr" rid="B7">Heimfarth et&#x20;al., 2021</xref>). In addition, PEC derivatives exhibited selective activity against tumor cells, exhibiting anti-carcinogenic activity (<xref ref-type="bibr" rid="B5">Deng et&#x20;al., 2020</xref>). In our previous study, PEC treatment exerted an anti-fibrotic effect in a mouse model of unilateral ureteral obstruction (UUO). However, the effect of PEC on HN remains unknown. The current study aimed to evaluate whether PEC could be a candidate for HN treatment and explore possible mechanisms.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Chemicals and Materials</title>
<p>Pectolinarigenin (PEC) was obtained from Chengdu Chroma-Biotechnology Co., Ltd. (purity &#x2265;99.0%). Antibodies against GAPDH, &#x3b1;-tubulin, fatty acid-binding protein (FABP4), IL-6, alpha-smooth muscle actin (&#x3b1;-SMA), janus kinase 2 (JAK2), p-JAK2, Smad3 and p-Smad3, and cleaved caspases 3 (C casp 3) were purchased from Hangzhou HuaAn Biotechnology Co., Ltd. (Hangzhou, China). Antibodies against Collagen-1(Col I), Fibronectin (FN), signal transducer and activator of transcription 3 (STAT3), p-STAT3, BAX, and Bcl2 were bought from Abcam (Cambridge, MA, United&#x20;States). Anti-TNF-&#x3b1; antibody was bought from Affinity Bioscience (Cincinnati, OH, United&#x20;States).</p>
</sec>
<sec id="s2-2">
<title>Animals</title>
<p>The HN model was established in male C57BL/6J mice (8&#x2013;10&#xa0;weeks old; 20&#x2013;25&#xa0;g) provided by the Animal Laboratory Center of Sichuan University (Chengdu, China). Forty mice were randomly assigned to five groups: Control (<italic>n</italic>&#x20;&#x3d; 8), HN (<italic>n</italic>&#x20;&#x3d; 8), Allopurinol (<italic>n</italic>&#x20;&#x3d; 8), PEC 25&#xa0;mg/kg (<italic>n</italic>&#x20;&#x3d; 8), PEC 50&#xa0;mg/kg (<italic>n</italic>&#x20;&#x3d; 8). The HN model was established by feeding mice with a mixture of adenine (0.16&#xa0;g/kg) and potassium oxonate (2.4&#xa0;g/kg) every other day for 4&#xa0;weeks, as previously described (<xref ref-type="bibr" rid="B21">Ren et&#x20;al., 2021</xref>). Allopurinol (10&#xa0;mg/kg) and PEC (25 and 50&#xa0;mg/kg) were orally given daily during the experiment along with HN establishment (for 4&#xa0;weeks). The mice were sacrificed, and the kidneys were collected at the end of study. Ethical approval was granted by the Animal Ethics Committee of West China Hospital of Sichuan University (No. 2020061A).</p>
</sec>
<sec id="s2-3">
<title>Histologic Examination</title>
<p>Tissue sections were fixed with 10% phosphate buffered formalin and embedded in paraffin after dehydrating. Kidney slides of 4-&#x3bc;m thickness were subject to PAS staining for morphologic analysis and Masson staining for fibrotic analysis (<xref ref-type="bibr" rid="B21">Ren et&#x20;al., 2021</xref>). Six pictures (&#xd7;400) per kidney were randomly captured by light microscopy for semiquantitative analysis. The tubular injury score was evaluated on the base of histopathology of injured/damaged renal tubules and was graded from 0 to 4 (0: 0%; 1: &#x3c;25%; 2: 26&#x2013;50%; 3: 51&#x2013;75%; 4: &#x2265;76% of injured/damaged renal tubules) (<xref ref-type="bibr" rid="B17">Liu et&#x20;al., 2015</xref>). The collagen positive area was measured by the ImageJ software.</p>
</sec>
<sec id="s2-4">
<title>Western Blotting Analysis</title>
<p>Total proteins were isolated from frozen kidney tissue or mouse kidney epithelial cells (TCMK-1, ATCC<sup>&#xae;</sup> CCL-139&#x2122;, Beijing bnbio Co., Ltd., Beijing, China) using radio immune precipitation (RIPA) lysis buffer (P0013B, Beyotime Biotechnology, China) and quantified using a Pierce&#x2122; BCA Protein Assay Kit (23225, Thermo Scientific, Billerica, MA, United&#x20;States). Equal amounts of protein lysate were separated on 10&#x2013;12% SDS-PAGE as previously described (<xref ref-type="bibr" rid="B21">Ren et&#x20;al., 2021</xref>). Immunoblots were visualized by the Immobilon Western Chemiluminescent HRP Substrate (WBKLS0500, Millipore Corporation, Billerica, MA, United&#x20;States) with Bio-Rad Chemi Doc MP and densitometered by ImageJ 6.0 software (National Institutes of Health, Bethesda, MD, United&#x20;States).</p>
</sec>
<sec id="s2-5">
<title>Immunohistochemistry Staining</title>
<p>Immunohistochemical staining was performed as previously described (<xref ref-type="bibr" rid="B21">Ren et&#x20;al., 2021</xref>). The following primary antibodies were used: anti-&#x3b1;-SMA (1:100, Huabio), anti-STAT3 (1:200, Abcam), anti-p-STAT3 (1:100, Abcam), anti-FABP4 (1:100, Huabio). Images were examined and acquired with an AxioCamHRc digital camera (Carl Zeiss, Jena, Germany).</p>
</sec>
<sec id="s2-6">
<title>Quantitative Real-Time PCR Analysis</title>
<p>Total RNA in kidney tissues of mice or TCMK-1 cells was isolated with a total RNA extraction Kit (TP-01121, Foregene, Chengdu, China) according to the manufacturer&#x2019;s instructions. The concentration of mRNA was determined by a Scan Drop 100 (Analytik Jena, Thuringia, Germany) determiner. Quantitative real-time PCR assays were performed on a PCR system (CFX Connect; Bio-Rad, Hercules, CA, United&#x20;States). The sequences of primers are shown in <xref ref-type="sec" rid="s11">Supplementary Table S1</xref>. Statistical analysis was conducted using the comparative 2<sup>&#x2212;&#x394;&#x394;CT</sup> method with GAPDH or <italic>&#x3b2;-actin</italic> as the internal standard.</p>
</sec>
<sec id="s2-7">
<title>RNA-Seq Transcriptomic Assay</title>
<p>Total RNA was extracted from kidney tissues with Trizol reagent (Invitrogen, Carlsbad, CA, United&#x20;States). Total RNA quality was assessed using the RNA 6000 Nano LabChip Kit (Agilent, CA, United&#x20;States) of the Agilent Bioanalyzer 2100 system. The RNA-seq were performed by LC-BIO Bio-tech Ltd. (Hangzhou, China). Differentially expressed genes were defined as those with fold changes &#x2265;1.5 and <italic>p</italic>&#x20;&#x2264; 0.05. Gene Ontology (GO) functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed using the OmicStudio tools at <ext-link ext-link-type="uri" xlink:href="https://www.omicstudio.cn/tool">https://www.omicstudio.cn/tool</ext-link>.</p>
</sec>
<sec id="s2-8">
<title>Cell Culture and Treatment</title>
<p>TCMK-1 cells were cultured in DMEM (Sigma-Aldrich) supplemented with 5% FBS (SH30084.03, Hyclone, Australia) in a humidified atmosphere (5% CO<sub>2</sub>, 37&#xb0;C). After incubating with DMEM containing 0.5% FBS for 24&#xa0;h, cells were exposed to UA (800&#xa0;&#x3bc;M) and treated with PEC of various concentrations (25, 50, 100, 150, and 300&#xa0;&#x3bc;M) for 24&#xa0;h.</p>
</sec>
<sec id="s2-9">
<title>Cell Viability Assay</title>
<p>A Cell Counting Kit-8 assay (CCK-8, Meilunbio, Dalian, China) was employed to assess cytotoxicity. Briefly, TCMK-1 cells were seeded into a 96-well plate at a density of 5,000&#x2013;10,000 cells/well and incubated with various concentrations of PEC (25, 50, 100, 150, and 300&#xa0;&#x3bc;M) with or without UA. Cells cultured in DMEM containing the same amount of DMSO were used as control. Twenty-four hours after incubation, the cells were incubated with 10% CCK-8 reagent for 1&#xa0;hour (37&#xb0;C, dark). Finally, the absorbance was detected by a microplate reader (Synergy Mx, Biotek, Winooski, VT, United&#x20;States) at a wavelength of 450&#xa0;nm.</p>
</sec>
<sec id="s2-10">
<title>Statistical Analysis</title>
<p>Results are presented as the mean&#x20;&#xb1; SD. Differences among multiple groups were compared using one-way analysis of variance (ANOVA) and a Tukey-Kramer <italic>post hoc</italic> test. Comparisons between two groups were performed using the two-tailed <italic>t</italic>&#x20;test. All statistics were performed using Prism software (ver. 6.01; GraphPad, San Diego, CA, United&#x20;States) and <italic>p</italic>&#x20;&#x3c; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Pectolinarigenin Lowered Serum Uric Acid Level, Improved Kidney Function, and Attenuated Renal Morphology in Hyperuricemic Nephropathy Mice</title>
<p>Administration of adenine and potassium oxonate successfully induced HN experimental mice as evidenced by increased serum UA level and aggravated kidney function. According to <xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>, the serum levels of UA (253.4&#x20;&#xb1; 14.49&#xa0;&#x3bc;M vs. 131.0&#x20;&#xb1; 5.631&#xa0;&#x3bc;M, <italic>p</italic>&#x20;&#x3c; 0.05), blood urea nitrogen (BUN) (13.00&#x20;&#xb1; 0.7513&#xa0;mM vs. 5.939&#x20;&#xb1; 0.2137&#xa0;mM, <italic>p</italic>&#x20;&#x3c; 0.05), and creatinine (63.86&#x20;&#xb1; 2.183&#xa0;&#x3bc;M vs. 20.33&#x20;&#xb1; 0.7468&#xa0;&#x3bc;M, <italic>p</italic>&#x20;&#x3c; 0.05) were significantly higher than those of control mice. After allopurinol and PEC treatment, the serum levels of UA, urea nitrogen, and creatinine were significantly decreased, and PEC at a dose of 25&#xa0;mg/kg seems more superior in reducing above indexes than PEC with a higher dose (50&#xa0;mg/kg). Observation of kidney changes in mice by PAS staining also showed that pathological changes in HN mice were alleviated by allopurinol and PEC treatment (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>). However, tubular injury scores of mice in the PEC 25&#xa0;mg/kg group were similar to those of the PEC 50&#xa0;mg/kg group, indicating no superiority of low dose PEC in attenuating renal histopathology (<xref ref-type="fig" rid="F1">Figure&#x20;1C</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Effects of PEC on serum UA and kidney function in HN mice. <bold>(A)</bold> Biochemical parameters (Serum UA, Serum creatinine, BUN) in mice. <bold>(B)</bold> PAS staining in the kidney. <bold>(C)</bold> Kidney injury score (<italic>n</italic>&#x20;&#x3d; 8). All data are represented as the mean&#x20;&#xb1; SD. &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fphar-12-792139-g001.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Analysis of Renal Transcriptome in Hyperuricemic Nephropathy Mice</title>
<p>To reveal the mechanism by which PEC improved kidney injury in HN mice, the RNA-seq analysis was applied. The results of volcano plot showed significantly different gene expression profile between control and HN mice (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>). Among these differentially expressed genes, 796 genes were up-regulated and 1,998 genes were down-regulated in kidneys of HN mice in comparison with control mice (<italic>p</italic>&#x20;&#x3c; 0.05). Remarkably, PEC 25&#xa0;mg/kg significantly reversed the change of 1,421&#x20;down-regulated and 293&#x20;up-regulated genes (<italic>p</italic>&#x20;&#x3c; 0.05) (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>). The significant PEC-modulated genes were illustrated by heatmap in <xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>, and genes related to apoptosis (Bax), inflammation (il1b, Tnf), and fibrosis (Col-1a1, Fn1) were seen. Further GO and KEGG analysis also suggested that these differentially expressed genes were involved in processes of lipid metabolism, apoptosis, inflammatory response, and fibrogenesis (<xref ref-type="fig" rid="F2">Figures&#x20;2D,E</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Effects of PEC on gene expression in kidneys of HN mice. <bold>(A)</bold> Volcano plot of gene expression difference between Control and HN groups. <bold>(B)</bold> Differentially regulated genes difference between Control, HN, and PEC 25&#xa0;mg/kg. <bold>(C)</bold> Heatmap of gene expression difference among Control, HN, and PEC 25&#xa0;mg/kg. <bold>(D)</bold> GO analysis of differentially expressed genes. <bold>(E)</bold> KEGG analysis of differentially expressed&#x20;genes.</p>
</caption>
<graphic xlink:href="fphar-12-792139-g002.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Pectolinarigenin Ameliorated Apoptosis, Reduced Expression of Proinflammatory Genes, and Improved Fibrosis in Kidneys of Hyperuricemic Nephropathy Mice</title>
<p>Consist with what transcriptome analysis found, the results from our western blot analysis showed that HN-induced kidney expression of apoptotic indicators was alleviated by PEC treatment (<xref ref-type="fig" rid="F3">Figures 3A,B</xref>) (<italic>p</italic>&#x20;&#x3c; 0.05). In addition, the expression of proinflammatory cytokines (IL-6, TNF-&#x3b1;, MCP-1) was significantly increased in kidneys of HN mice and further decreased by PEC treatment (<xref ref-type="fig" rid="F3">Figure&#x20;3C</xref>) (<italic>p</italic>&#x20;&#x3c; 0.05). Moreover, Masson&#x2019;s staining (blue) revealed a remarkable increase of renal interstitial fibrosis in HN mice, which was ameliorated by PEC (<xref ref-type="fig" rid="F4">Figure&#x20;4</xref>) (<italic>p</italic>&#x20;&#x3c; 0.05). Accordingly, the elevated accumulation of fibrotic markers of &#x3b1;-SMA, Col I, and FN was observed in kidneys of HN mice, and PEC significantly reduced the accumulation of these corresponding genes (<xref ref-type="fig" rid="F5">Figure&#x20;5</xref>) (<italic>p</italic>&#x20;&#x3c; 0.05). The above results illustrated that PEC alleviated renal apoptosis, inflammation, and fibrosis in HN&#x20;mice.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Effects of PEC on kidney apoptosis and inflammation in HN mice. <bold>(A,B)</bold> The Bcl2/Bax, Cleaved caspase 3 (C casp 3) protein levels normalized by &#x3b2;-actin. <bold>(C)</bold> The mRNA expressions of IL-6, TNF&#x3b1;, and MCP-1 measured by real-time PCR analysis. All data are represented as the mean&#x20;&#xb1; SD. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fphar-12-792139-g003.tif"/>
</fig>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Effects of PEC on kidney fibrosis in HN mice. <bold>(A)</bold> Masson&#x2019;s trichrome staining of mouse kidneys (&#xd7;200 and &#xd7;400). <bold>(B)</bold> Quantitation of positive area in Masson&#x2019;s trichrome staining (<italic>n</italic>&#x20;&#x3d; 8). All data are represented as the mean&#x20;&#xb1; SD. &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fphar-12-792139-g004.tif"/>
</fig>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Effects of PEC on kidney fibrotic expression in HN mice. <bold>(A)</bold> Photomicrographs of &#x3b1;-SMA immunostaining in kidneys of mice (&#xd7;200 and &#xd7;400). <bold>(B,C)</bold> The &#x3b1;-SMA, FN, and Col I protein levels normalized by &#x3b1;-tubulin. All data are represented as the mean&#x20;&#xb1; SD. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fphar-12-792139-g005.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>Pectolinarigenin Downregulated the Expression of FABP4 in the Kidneys of Hyperuricemic Nephropathy Mice</title>
<p>Our early study indicated that the lipid-binding chaperone FABP4 was increased in kidneys of HN mice and played&#x20;crucial role in HUA-induced renal inflammation and fibrosis (<xref ref-type="bibr" rid="B22">Shi et&#x20;al., 2020a</xref>). In line with our previous findings, the expression of FABP4 in kidneys of HN mice was&#x20;significantly increased (<italic>p</italic>&#x20;&#x3c; 0.05). PEC treatment largely&#x20;inhibited the expression of FABP4 both in the mRNA and protein level, further demonstrating the role of PEC in HUA-induced inflammation and fibrosis (<xref ref-type="fig" rid="F6">Figure&#x20;6</xref>) (<italic>p</italic>&#x20;&#x3c;&#x20;0.05).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Effects of PEC on FABP4 expression in kidneys of HN mice. <bold>(A)</bold> Photomicrographs of &#x3b1;-SMA immunostaining in kidneys of mice (&#xd7;200 and &#xd7;400). <bold>(B)</bold> The FABP4 protein level normalized by &#x3b1;-tubulin. <bold>(C)</bold> The mRNA expressions of FABP4 measured by real-time PCR analysis. All data are represented as the mean&#x20;&#xb1; SD (<italic>n</italic>&#x20;&#x3d; 3). &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fphar-12-792139-g006.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>Pectolinarigenin Suppressed the TGF-&#x3b2;/SMAD3 and JAK2/STAT3 Signaling Pathway in the Kidneys of Hyperuricemic Nephropathy Mice</title>
<p>As the most potent fibrogenic factor, TGF-&#x3b2; was considered to contribute to HUA-mediated renal fibrosis via the activation of Smad3 (<xref ref-type="bibr" rid="B17">Liu et&#x20;al., 2015</xref>). To investigate the effect of PEC on the activation of TGF-&#x3b2;/Smad3 signaling in mice of HN, we measured the expression of TGF-&#x3b2; by western blot analysis. It was shown that TGF-&#x3b2; expression was significantly increased in kidneys of HN mice and decreased by PEC treatment (<xref ref-type="fig" rid="F7">Figure&#x20;7</xref>) (<italic>p</italic>&#x20;&#x3c; 0.05). Meanwhile, kidney injury resulted in the phosphorylation of Smad3, which was remarkedly suppressed by PEC (<xref ref-type="fig" rid="F7">Figure&#x20;7</xref>) (<italic>p</italic>&#x20;&#x3c; 0.05). Altogether, these results suggested that PEC could inhibit activation of TGF-&#x3b2;/Smad3 signaling pathway in the kidneys of HN&#x20;mice.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Effects of PEC on the activation of TGF-&#x3b2;/SMAD3 signaling in kidneys of HN mice. <bold>(A,B)</bold> The TGF-&#x3b2; and p-Smad3/Smad3 protein levels normalized by &#x3b1;-tubulin. All data are represented as the mean&#x20;&#xb1; SD (<italic>n</italic>&#x20;&#x3d; 3). &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fphar-12-792139-g007.tif"/>
</fig>
<p>STAT3 is a cytoplasmic transcription factor that could elicit diverse biological outcomes. Considerable studies have elucidated the role of STAT3 in mediating HUA-induced renal inflammation, apoptosis, and fibrosis (<xref ref-type="bibr" rid="B23">Shi et&#x20;al., 2020b</xref>; <xref ref-type="bibr" rid="B19">Pan et&#x20;al., 2021</xref>). To examine whether PEC could abrogate the activation of STAT3 in HN, the immunochemical staining and western blot analysis was employed to measure the expression of phosphorylated STAT3 (p-STAT3). As shown by <xref ref-type="fig" rid="F8">Figure&#x20;8</xref>, the phosphorylation level of STAT3 was significantly increased in kidneys of HN mice, which was restored by PEC (<xref ref-type="fig" rid="F8">Figure&#x20;8</xref>) (<italic>p</italic>&#x20;&#x3c; 0.05). Additionally, immunochemical staining showed that HN-induced p-STAT3 was mainly located in renal tubules (<xref ref-type="fig" rid="F8">Figures&#x20;8A,B</xref>).</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Effects of PEC on the activation of JAK2/STAT3 signaling in kidneys of HN mice. <bold>(A,B)</bold> Photomicrographs of STAT3 and p-STAT3 immunostaining in kidneys of mice (&#xd7;200 and &#xd7;400). <bold>(C,D)</bold> The p-JAK2/JAK2 and p-STAT3/STAT3 protein levels normalized by &#x3b1;-tubulin. All data are represented as the mean&#x20;&#xb1; SD (<italic>n</italic>&#x20;&#x3d; 3). &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a; &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fphar-12-792139-g008.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>Pectolinarigenin Inhibited Proinflammatory and Fibrotic Expression in Uric Acid-Stimulated TCMK-1 Cells</title>
<p>To further investigate the role of PEC in HN, TCMK-1 cells were treated with soluble UA (800&#xa0;&#x3bc;M) for 24&#xa0;h. As shown in <xref ref-type="fig" rid="F9">Figure&#x20;9A</xref>, PEC under 150&#xa0;&#x3bc;M showed no cytotoxic effect for TCMK-cells and cells treated with PEC at 100&#xa0;&#x3bc;M showed the highest cell viability. UA stimulation led to increased expression of IL-6, TNF-&#x3b1;, and FABP4 in TCMK-1 cells, and PEC (100&#xa0;&#x3bc;M) significantly suppressed such expression (<xref ref-type="fig" rid="F9">Figures 9B&#x2013;D</xref>) (<italic>p</italic>&#x20;&#x3c; 0.05). Meanwhile, the fibrotic expression of &#x3b1;-SMA, FN, and Col I in UA-treated TCMK-1 cells was reduced by PEC (100&#xa0;&#x3bc;M) (<xref ref-type="fig" rid="F9">Figures 9B&#x2013;D</xref>) (<italic>p</italic>&#x20;&#x3c; 0.05), thus confirming the anti-inflammatory and anti-fibrotic effects of PEC <italic>in&#x20;vitro</italic>.</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>Effects of PEC on the proinflammatory and fibrotic expression in UA-treated TCMK-1 cells. <bold>(A)</bold> Cytotoxicity of PEC-treated TCMK-1cells with or without UA. <bold>(B)</bold> The mRNA expressions of IL-6, TNF&#x3b1;, FABP4, &#x3b1;-SMA, FN, and Col I measured by real-time PCR analysis. <bold>(C,D)</bold> The IL-6, TNF&#x3b1;, FABP4, &#x3b1;-SMA, FN, and Col I protein levels normalized by GAPDH. All data are represented as the mean&#x20;&#xb1; SD (<italic>n</italic>&#x20;&#x3d; 3). &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001, &#x23;<italic>p</italic>&#x20;&#x3c; 0.05 compared with UA-treated cells, ns means no significance.</p>
</caption>
<graphic xlink:href="fphar-12-792139-g009.tif"/>
</fig>
</sec>
<sec id="s3-7">
<title>Pectolinarigenin Hindered TGF-&#x3b2;/SMAD3 and JAK2/STAT3 Activation in Uric Acid-Induced TCMK-1 Cells</title>
<p>After UA treatment, the expression of TGF-&#x3b2; and phosphorylated Smad3 were significantly increased in TCMK-1 cells, indicating that HUA could directly activate the TGF-&#x3b2;/Smad3 signaling pathway (<xref ref-type="fig" rid="F10">Figures 10A,B</xref>) (<italic>p</italic>&#x20;&#x3c; 0.05). PEC (100&#xa0;&#x3bc;M) successfully suppressed the expression of TGF-&#x3b2; and the phosphorylation of Smad3 indued by UA (<xref ref-type="fig" rid="F10">Figures 10A,B</xref>) (<italic>p</italic>&#x20;&#x3c; 0.05). Similarly, UA stimulation resulted in the phosphorylation of JAK2 and STAT3, which was abrogated by PEC treatment (100&#xa0;&#x3bc;M) (<xref ref-type="fig" rid="F10">Figures 10C,D</xref>) (<italic>p</italic>&#x20;&#x3c; 0.05). Hence, consistent with our <italic>in vivo</italic> findings, PEC (100&#xa0;&#x3bc;M) could inhibit the TGF-&#x3b2;/Smad3 and JAK2/STAT3 activation in UA-treated TCMK-1&#x20;cells.</p>
<fig id="F10" position="float">
<label>FIGURE 10</label>
<caption>
<p>Effects of PEC on the activation of TGF-&#x3b2;/SMAD3 and JAK2/STAT3 signaling pathways in UA-stimulated TCMK-1 cells. <bold>(A,B)</bold> The TGF-&#x3b2; and p-Smad3/Smad3 protein levels normalized by GAPDH. <bold>(C,D)</bold> The p-IAK2/JAK2 and p-STAT3/STAT3 protein levels normalized by &#x3b1;-tubulin. All data are represented as the mean&#x20;&#xb1; SD (<italic>n</italic>&#x20;&#x3d; 3). &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fphar-12-792139-g010.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Generally, UA is an antioxidant agent in a physiological medium (<xref ref-type="bibr" rid="B3">Dalbeth et&#x20;al., 2021</xref>). Disturbance of the balance between UA production and excretion would lead to HUA that is considered as an independent risk factor for CKD progression (<xref ref-type="bibr" rid="B9">Johnson et&#x20;al., 2013</xref>). Persistently high-serum UA levels was reported to trigger kidney inflammation and fibrosis that might contribute to HN (<xref ref-type="bibr" rid="B13">Lee et&#x20;al., 2021</xref>). Current standard treatment for HUA is UA-lowering drugs represented by XO inhibitors and uricosuric agents, the nephroprotective effect of which remains controversy in CKD patients (<xref ref-type="bibr" rid="B18">Liu et&#x20;al., 2021</xref>). Consequently, novel effective drugs for the prevention and treatment of HN need to be explored.</p>
<p>PEC is a natural flavonoid that showed therapeutic potential for inflammatory diseases, diabetes, and several types of cancers (<xref ref-type="bibr" rid="B2">Cheriet et&#x20;al., 2020</xref>). Meanwhile, PEC could alleviate renal fibrosis in mice undergoing unilateral ureteral obstruction (UUO) (<xref ref-type="bibr" rid="B15">Li et&#x20;al., 2021</xref>). However, the effects and underlying mechanism of PEC against HN remains unclear. In the present study, we noticed that PEC improved both HUA and renal damage in adenine and potassium oxonate-treated mice, as evidenced by reduced serum levels of UA, blood urea nitrogen (BUN), and creatinine and attenuated renal pathological changes. Remarkably, it was noticed that PEC at a dose of 25&#xa0;mg/kg was more efficient in alleviating above biochemical parameters than PEC at a dose of 50&#xa0;mg/kg. This might be explained by side effects of increased dosage as cytotoxicity effects of PEC have been reported by early studies (<xref ref-type="bibr" rid="B11">Lee et&#x20;al., 2018</xref>). Moreover, PEC attenuated HUA-induced apoptosis characterized by the imbalance of Bcl-2/Bax and increased expression of cleaved caspase 3, suggesting the nephroprotective effects of PEC in&#x20;HN.</p>
<p>Accumulation of UA increased the levels of inflammatory cytokines to mediate kidney injury (<xref ref-type="bibr" rid="B16">Li et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B25">Xu et&#x20;al., 2021</xref>). In line with this, the elevated expression of IL-6, TNF-&#x3b1;, and MCP-1 were noticed in kidneys of HN mice and UA-stimulated TCMK-1cells, which was inhibited by PEC. The lipid transporter FABP4 is a potential mediator of inflammatory responses that has been suggested to play a crucial role in mediating renal inflammation and fibrosis in HN (<xref ref-type="bibr" rid="B8">Hotamisligil and Bernlohr, 2015</xref>; <xref ref-type="bibr" rid="B22">Shi et&#x20;al., 2020a</xref>). Our results showed that PEC suppressed HUA-induced FABP4 expression, further illustrating its anti-inflammatory effects of PEC in&#x20;HN.</p>
<p>Kidney fibrosis, the ultimate pathological outcome of HN, is characterized by the expression of mesenchymal cell products such as &#x3b1;-SMA, FN, and Col I (<xref ref-type="bibr" rid="B13">Lee et&#x20;al., 2021</xref>). The TGF-&#x3b2;/Smad3 signaling pathway plays a critical role in mediating profibrotic response of renal epithelial cells and activating renal fibroblasts (<xref ref-type="bibr" rid="B17">Liu et&#x20;al., 2015</xref>). TGF-&#x3b2; interacts with its receptors to phosphorylate Smad2/3 and subsequently regulates the transcription of profibrotic genes (<xref ref-type="bibr" rid="B28">Zhang et&#x20;al., 2018</xref>). It was observed that HUA activated the TGF-&#x3b2;/Smad3 signaling pathway in HN mice (<xref ref-type="bibr" rid="B1">Balakumar et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B23">Shi et&#x20;al., 2020b</xref>). In this study, we noticed that PEC successfully diminished HUA-induced TGF-&#x3b2; expression and Smad3 phosphorylation, which is in agreement with our previous finding that PEC blocked TGF&#x3b2;1-induced SMAD3 phosphorylation in fibroblast (<xref ref-type="bibr" rid="B15">Li et&#x20;al., 2021</xref>). Meanwhile, PEC significantly reduced the expression of &#x3b1;-SMA, FN, and Col I induced by HUA, suggesting that PEC suppressed the TGF&#x3b2;1/Smad3 signaling pathway to alleviate kidney fibrosis in HN&#x20;mice.</p>
<p>Considerable studies have implicated that activation of STAT3 via the IL-6/JAK2 cascade mediated inflammation and fibrosis in HN (<xref ref-type="bibr" rid="B21">Ren et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B24">Wu et&#x20;al., 2021</xref>). Pharmacological inhibition of STAT3 was reported to attenuate kidney injury, slow down fibrosis, and suppress multiple proinflammatory cytokine production in kidneys of HN mice (<xref ref-type="bibr" rid="B19">Pan et&#x20;al., 2021</xref>). Studies have identified PEC as a STAT3 inhibitor to suppress tumor growth and metastasis (<xref ref-type="bibr" rid="B27">Zhang et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B6">Gan et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B14">Li et&#x20;al., 2019</xref>). Our previous study also indicated that PEC inhibited the activation of STAT3 in kidneys of UUO mice (<xref ref-type="bibr" rid="B15">Li et&#x20;al., 2021</xref>). In the current study, treatment with PEC suppressed the phosphorylation of STAT3 signaling in kidneys of HN mice and UA-induced TCMK-1 cells, which might be the mechanism by which PEC ameliorated kidney inflammation and fibrosis in&#x20;HN.</p>
<p>In summary, anti-hyperuricemic and nephroprotective effects of PEC were firstly demonstrated in adenine and potassium oxonate-induced HN mice and UA-treated TCMK-1 cells. Our results suggested that PEC attenuated kidney inflammation and fibrosis induced by HUA. Mechanically, we found that the nephroprotective effects of PEC were associated with the inhibition of the Smad3 and STAT3 signaling pathways. Taken together, PEC may be a candidate drug for the treatment of hyperuricemic nephropathy.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The data presented in the study are accessible in the GEO repository, accession number GSE190205. The study can also be seen at: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE190205">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc&#x003D;GSE190205</ext-link>
</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The animal study was reviewed and approved by the Animal Ethics Committee of West China Hospital of Sichuan University (No. 2020061A).</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>LM, ZT, and PF designed the study; BW, QR, FG, and RH carried out experiments and analyzed the data; QR and BW made the figures, drafted and revised the paper; all authors approved the final version of the manuscript.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This research was supported by grants from the National Natural Science Foundation of China (82060131), Key Research Program of Sichuan Province (2021YFQ0027), and the Science/Technology Project of Sichuan province (2020YFS0224).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2021.792139/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2021.792139/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.DOCX" id="SM1" mimetype="application/DOCX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balakumar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Alqahtani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>Mahadevan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dhanaraj</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Mechanistic Insights into Hyperuricemia-Associated Renal Abnormalities with Special Emphasis on Epithelial-To-Mesenchymal Transition: Pathologic Implications and Putative Pharmacologic Targets</article-title>. <source>Pharmacol. Res.</source> <volume>161</volume>, <fpage>105209</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2020.105209</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheriet</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ben-Bachir</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Thamri</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Seghiri</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mancini</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Isolation and Biological Properties of the Natural Flavonoids Pectolinarin and Pectolinarigenin-A Review</article-title>. <source>Antibiotics</source> <volume>9</volume>, <fpage>417</fpage>. <pub-id pub-id-type="doi">10.3390/antibiotics9070417</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalbeth</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gosling</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Gaffo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Abhishek</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Gout</article-title>. <source>Lancet</source> <volume>397</volume>, <fpage>1843</fpage>&#x2013;<lpage>1855</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(21)00569-9</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dehlin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jacobsson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Roddy</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Global Epidemiology of Gout: Prevalence, Incidence, Treatment Patterns and Risk Factors</article-title>. <source>Nat. Rev. Rheumatol.</source> <volume>16</volume>, <fpage>380</fpage>&#x2013;<lpage>390</lpage>. <pub-id pub-id-type="doi">10.1038/s41584-020-0441-1</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Pectolinarigenin Inhibits Cell Viability, Migration and Invasion and Induces Apoptosis via a ROS-Mitochondrial Apoptotic Pathway in Melanoma Cells</article-title>. <source>Oncol. Lett.</source> <volume>20</volume>, <fpage>116</fpage>. <pub-id pub-id-type="doi">10.3892/ol.2020.11977</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Natural Product Pectolinarigenin Exhibits Potent Anti-metastatic Activity in Colorectal Carcinoma Cells <italic>In Vitro</italic> and <italic>In Vivo</italic>
</article-title>. <source>Bioorg. Med. Chem.</source> <volume>27</volume>, <fpage>115089</fpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2019.115089</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heimfarth</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nascimento</surname>
<given-names>L. d. S.</given-names>
</name>
<name>
<surname>Amazonas Da Silva</surname>
<given-names>M. d. J.</given-names>
</name>
<name>
<surname>Lucca Junior</surname>
<given-names>W. d.</given-names>
</name>
<name>
<surname>Lima</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Quintans-Junior</surname>
<given-names>L. J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Neuroprotective and Anti-inflammatory Effect of Pectolinarigenin, a Flavonoid from Amazonian <italic>Aegiphila integrifolia</italic> (Jacq.), against Lipopolysaccharide-Induced Inflammation in Astrocytes via NF&#x3ba;B and MAPK Pathways</article-title>. <source>Food Chem. Toxicol.</source> <volume>157</volume>, <fpage>112538</fpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2021.112538</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hotamisligil</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Bernlohr</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Metabolic Functions of FABPs-Mmechanisms and Therapeutic Implications</article-title>. <source>Nat. Rev. Endocrinol.</source> <volume>11</volume>, <fpage>592</fpage>&#x2013;<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1038/nrendo.2015.122</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jalal</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>S&#xe1;nchez-Lozada</surname>
<given-names>L. G.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Ritz</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Uric Acid and Chronic Kidney Disease: Which is Chasing Which?</article-title>. <source>Nephrol. Dial. Transpl.</source> <volume>28</volume>, <fpage>2221</fpage>&#x2013;<lpage>2228</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gft029</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Landa</surname>
<given-names>C. E. M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Renal Effects of Hyperuricemia</article-title>. <source>Contrib. Nephrol.</source> <volume>192</volume>, <fpage>8</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1159/000484273</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Venkatarame Gowda Saralamma</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Vetrivel</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E. H.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Comparative Proteomic Profiling of Tumor-Associated Proteins in Human Gastric Cancer Cells Treated with Pectolinarigenin</article-title>. <source>Nutrients</source> <volume>10</volume>, <fpage>1596</fpage>. <pub-id pub-id-type="doi">10.3390/nu10111596</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.&#x20;C.</given-names>
</name>
<name>
<surname>Um</surname>
<given-names>B. H.</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>L. S.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Pectolinarigenin, an Aglycone of Pectolinarin, Has More Potent Inhibitory Activities on Melanogenesis Than Pectolinarin</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>493</volume>, <fpage>765</fpage>&#x2013;<lpage>772</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2017.08.106</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.&#x20;J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H. Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy</article-title>. <source>Diagnostics</source> <volume>11</volume>. <pub-id pub-id-type="doi">10.3390/diagnostics11091674</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Inhibition of Stat3 Signaling Pathway by Natural Product Pectolinarigenin Attenuates Breast Cancer Metastasis</article-title>. <source>Front. Pharmacol.</source> <volume>10</volume>, <fpage>1195</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2019.01195</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Natural Flavonoid Pectolinarigenin Alleviated Kidney Fibrosis via Inhibiting the Activation of TGF&#x3b2;/SMAD3 and JAK2/STAT3 Signaling</article-title>. <source>Int. Immunopharmacol</source> <volume>91</volume>, <fpage>107279</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2020.107279</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Nox4 Has a Crucial Role in Uric Acid-Induced Oxidative Stress and Apoptosis in Renal Tubular Cells</article-title>. <source>Mol. Med. Rep.</source> <volume>13</volume>, <fpage>4343</fpage>&#x2013;<lpage>4348</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2016.5083</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy</article-title>. <source>J.&#x20;Am. Soc. Nephrol.</source> <volume>26</volume>, <fpage>2716</fpage>&#x2013;<lpage>2729</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2014080793</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia: A Network Meta-Analysis of Randomized Controlled Trials</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>690557</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.690557</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Pharmacologic Inhibiting STAT3 Delays the Progression of Kidney Fibrosis in Hyperuricemia-Induced Chronic Kidney Disease</article-title>. <source>Life Sci.</source> <volume>285</volume>, <fpage>119946</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2021.119946</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pascart</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liot&#xe9;</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Gout: State of the Art After a Decade of Developments</article-title>. <source>Rheumatology</source> <volume>58</volume>, <fpage>27</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/key002</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Natural Flavonol Fisetin Attenuated Hyperuricemic Nephropathy via Inhibiting IL-6/JAK2/STAT3 and TGF-&#x3b2;/SMAD3 Signaling</article-title>. <source>Phytomedicine</source> <volume>87</volume>, <fpage>153552</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2021.153552</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020a</year>). <article-title>Pharmacological Inhibition of Fatty Acid-Binding Protein 4 Alleviated Kidney Inflammation and Fibrosis in Hyperuricemic Nephropathy</article-title>. <source>Eur. J.&#x20;Pharmacol.</source> <volume>887</volume>, <fpage>173570</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173570</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020b</year>). <article-title>Delayed Treatment with an Autophagy Inhibitor 3-MA Alleviates the Progression of Hyperuricemic Nephropathy</article-title>. <source>Cell Death Dis.</source> <volume>11</volume>, <fpage>467</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-020-2673-z</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.-L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.-F.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L.-Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.-L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.-H.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>C.-J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The Extract of Sonneratia Apetala Leaves and Branches Ameliorates Hyperuricemia in Mice by Regulating Renal Uric Acid Transporters and Suppressing the Activation of the JAK/STAT Signaling Pathway</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>698219</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.698219</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Mai</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Anti-Hyperuricemic and Nephroprotective Effects of Dihydroberberine in Potassium Oxonate- and Hypoxanthine-Induced Hyperuricemic Mice</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>645879</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.645879</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yanai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Adachi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hakoshima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Katsuyama</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease</article-title>. <source>Int. J.&#x20;Mol. Sci.</source> <volume>22</volume>. <pub-id pub-id-type="doi">10.3390/ijms22179221</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Natural Product Pectolinarigenin Inhibits Osteosarcoma Growth and Metastasis via SHP-1-Mediated STAT3 Signaling Inhibition</article-title>. <source>Cell Death Dis.</source> <volume>7</volume>, <fpage>e2421</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2016.305</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X. M.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X. R.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>H. Y.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The Preventive and Therapeutic Implication for Renal Fibrosis by Targetting TGF-&#x3b2;/Smad3 Signaling</article-title>. <source>Clin. Sci.</source> <volume>132</volume>, <fpage>1403</fpage>&#x2013;<lpage>1415</lpage>. <pub-id pub-id-type="doi">10.1042/CS20180243</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>